The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

Felmetatug vedotin’s exit could be bad news for Mersana.

AstraZeneca bags three of the month’s four oncology approvals.

Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.

Firce-1 is scrapped after showing dismal response rates and patient deaths.

But the new focus on a predictive biomarker could cut the market in half.